SUPPLEMENT

Q1 2021 — Financial disclosures

Q1 2021PDF · 9 pages954 KB
Merck & Co., Inc.
Financial Highlights Package
First Quarter 2021
Table of Contents
Table 1: 	GAAP P&L..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2
Table 2a: GAAP to Non-GAAP Reconciliation 1Q21 ........................3
Table 2b: GAAP to Non-GAAP Reconciliation 1Q20.........................4
Table 3: Sales – Current Year and Prior Year by Quarter ...............5
Table 3a: Sales – U.S. / Ex- U.S. 1Q21.............................................6
Table 3b: Sales – Pharmaceutical Geographic Split .........................7
Table 4: Other (Income) Expense ....................................................8

-- 1 of 9 --

Sales 	12,080	$ 	12,057	$ 	0%
Costs, Expenses and Other
Cost of sales 	3,670 	3,312 	11%
Selling, general and administrative 	2,633 	2,555 	3%
Research and development 	2,465 	2,209 	12%
Restructuring costs (1) 298 	72 	*
Other (income) expense, net 	(448) 	71 	*
Income Before Taxes 	3,462 	3,838 	-10%
Taxes on Income 	276 	619
Net Income 	3,186 	3,219 	-1%
Less: Net Income Attributable to Noncontrolling Interests 	7 	-
Net Income Attributable to Merck & Co., Inc. 	3,179	$ 	3,219	$ 	-1%
Earnings per Common Share Assuming Dilution 	1.25	$ 	1.26	$ 	-1%
Average Shares Outstanding Assuming Dilution 	2,541 	2,547
Tax Rate (2) 8.0% 	16.1%
* 100% or greater
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
(2) The effective income tax rate for the first quarter of 2021 reflects a net tax benefit of $237 million related to the settlement of
certain federal income tax matters.
(1) Represents separation and other related costs associated with restructuring activities under the company's formal
restructuring programs.
1Q20	1Q21
GAAP
% Change
1

-- 2 of 9 --

. 	.
Sales 	12,080	$ 	12,057	$ 	10,872	$ 	12,551	$ 	12,514	$ 	47,994	$ 	0%
Costs, Expenses and Other
Cost of sales 	3,670 	3,312 	3,159 	3,481 	5,532 	15,485 	11%
Selling, general and administrative 	2,633 	2,555 	2,378 	2,450 	3,086 	10,468 	3%
Research and development 	2,465 	2,209 	2,123 	3,390 	5,838 	13,558 	12%
Restructuring costs 	298 	72 	83 	114 	309 	578 	*
Other (income) expense, net 	(448) 	71 	(390) 	(312) 	(258) 	(886) 	*
Income (Loss) Before Taxes 	3,462 	3,838 	3,519 	3,428 	(1,993) 	8,791 	-10%
Taxes on Income 	276 	619 	509 	483 	99 	1,709
Net Income (Loss) 	3,186 	3,219 	3,010 	2,945 	(2,092) 	7,082 	-1%
Less: Net Income Attributable to Noncontrolling Interests 	7 	- 	8 	4 	2 	15
Net Income (Loss) Attributable to Merck & Co., Inc. 	3,179	$ 	3,219	$ 	3,002	$ 	2,941	$ 	(2,094)	$ 	7,067	$ 	-1%
Earnings (Loss) per Common Share Assuming Dilution (1) 1.25	$ 	1.26	$ 	1.18	$ 	1.16	$ 	(0.83)	$ 	2.78	$ 	-1%
Average Shares Outstanding Assuming Dilution (1) 2,541 	2,547 	2,536 	2,538 	2,530 	2,541
Tax Rate 	8.0% 	16.1% 	14.5% 	14.1% 	-5.0% 	19.4%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share
assuming dilution as the effect would have been anti-dilutive.
2Q 	3Q 	4Q 	Full Year 	1Q	1Q 	1Q
2021 	2020 	% Change
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2

-- 3 of 9 --

Cost of sales 	3,670	$ 	517 	27 	188 (3) 732 	2,938	$
Selling, general and administrative 	2,633 	218 	3 	221 	2,412
Research and development 	2,465 	18 	7 	25 	2,440
Restructuring costs 	298 	298 	298 	-
Other (income) expense, net 	(448) 	(28) 	(561) 	(589) 	141
Income Before Taxes 	3,462 	(725) 	(335) 	561 	(188) 	(687) 	4,149
Income Tax Provision (Benefit) 	276 	(114) (4) (41) (4) 123 (4) (278) (4) (310) 	586
Net Income 	3,186 	(611) 	(294) 	438 	90 	(377) 	3,563
Net Income Attributable to Merck & Co., Inc. 	3,179 	(611) 	(294) 	438 	90 	(377) 	3,556
Earnings per Common Share Assuming Dilution 	1.25	$ 	(0.24) 	(0.12) 	0.17 	0.04 	(0.15) 	1.40	$
Tax Rate 	8.0% 	14.1%
Only the line items that are affected by non-GAAP adjustments are shown.
(1) Amount included in cost of sales primarily reflects expenses for the amortization of intangible assets. Amount included in selling, general and administrative expenses reflects approximately $208 million of
expenses related to the company's planned spin-off of Organon & Co. and other acquisition and divestiture-related costs. Amount included in other (income) expense, net, primarily reflects royalty income, partially
offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items also include a $237 million net tax
benefit related to the settlement of certain federal income tax matters.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends.
Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses
these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part
using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
Certain Other
Items
(3) Represents a charge for the discontinuation of COVID-19 development programs.
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FIRST QUARTER 2021
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
(Income) Loss
from Investments
in Equity
Securities
Adjustment
Subtotal
3

-- 4 of 9 --

Cost of sales 	3,312	$ 	407 	68 	475 	2,837	$
Selling, general and administrative 	2,555 	278 	11 	289 	2,266
Research and development 	2,209 	40 	17 	57 	2,152
Restructuring costs 	72 	72 	72 	-
Other (income) expense, net 	71 	(11) 	(87) 	(98) 	169
Income Before Taxes 	3,838 	(714) 	(168) 	87 	(795) 	4,633
Income Tax Provision (Benefit) 	619 	(175) (3) (7) (3) 19 (3) (163) 	782
Net Income 	3,219 	(539) 	(161) 	68 	(632) 	3,851
Net Income Attributable to Merck & Co., Inc. 	3,219 	(539) 	(161) 	68 	(632) 	3,851
Earnings per Common Share Assuming Dilution 	1.26	$ 	(0.21) 	(0.06) 	0.02 	(0.25) 	1.51	$
Tax Rate 	16.1% 	17.0%
Only the line items that are affected by non-GAAP adjustments are shown.
Table 2b
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION*
FIRST QUARTER 2020
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects expenses for the amortization of intangible assets. Amount included in selling, general and administrative expenses reflects approximately
$165 million of expenses related to the company's planned spin-off of Organon & Co., approximately $95 million of costs related to the acquisition of ArQule, Inc., and other acquisition and
divestiture-related costs. Amount included in research and development expenses primarily reflects expenses related to a net increase in the estimated fair value measurement of liabilities for
contingent consideration. Amount included in other (income) expense, net, primarily reflects royalty income, partially offset by an increase in the estimated fair value measurement of liabilities
for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
(Income) Loss
from Investments
in Equity
Securities
Adjustment
Subtotal Non-GAAP
*As previously disclosed, beginning in 2021, the Company has changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded
the amortization of intangible assets recognized in connection with business acquisitions, but did not exclude the amortization of intangibles originating from collaborations, asset acquisitions or
licensing arrangements. In 2021, Merck’s non-GAAP results no longer differentiate between the nature of intangibles amortization and exclude all amortization of intangible assets. Also,
beginning in 2021, Merck’s non-GAAP results exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in
investment funds. These amounts are difficult to predict and can fluctuate significantly period to period affecting comparability of results. Non-GAAP results for the comparable periods of 2020
have been recast to conform to the new presentation.
4

-- 5 of 9 --

2021
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch %
TOTAL SALES (1) $12,080 	$12,057 	$10,872 	$12,551 	$12,514 	$47,994 	- 	-1
PHARMACEUTICAL 	10,675 	10,655 	9,679 	11,320 	11,367 	43,021 	- 	-3
Oncology
Keytruda 	3,899 	3,284 	3,388 	3,715 	3,993 	14,380 	19 	16
Alliance Revenue – Lynparza (2) 228 	145 	178 	196 	206 	725 	57 	51
Alliance Revenue – Lenvima (2) 130 	128 	151 	142 	158 	580 	1 	-1
Vaccines (3)
Gardasil / Gardasil 9 	917 	1,097 	656 	1,187 	998 	3,938 	-16 	-20
ProQuad / M-M-R II / Varivax 	449 	435 	378 	576 	488 	1,878 	3 	2
Pneumovax 23 	171 	256 	117 	375 	339 	1,087 	-33 	-36
RotaTeq 	158 	222 	168 	210 	196 	797 	-29 	-29
Vaqta 	34 	60 	28 	51 	31 	170 	-43 	-44
Hospital Acute Care
Bridion 	340 	299 	224 	320 	355 	1,198 	14 	11
Prevymis 	82 	60 	63 	77 	80 	281 	37 	31
Noxafil 	67 	94 	73 	79 	82 	329 	-29 	-32
Primaxin 	65 	51 	64 	74 	62 	251 	26 	17
Cancidas 	57 	55 	43 	50 	65 	213 	4 	1
Invanz 	57 	64 	43 	51 	53 	211 	-12 	-11
Zerbaxa 	(8) 	37 	32 	43 	19 	130 	-121 	-120
Immunology
Simponi 	214 	215 	191 	209 	223 	838 	- 	-8
Remicade 	85 	88 	73 	82 	88 	330 	-3 	-9
Neuroscience
Belsomra 	79 	79 	84 	81 	83 	327 	- 	-4
Virology
Isentress / Isentress HD 	209 	245 	196 	205 	211 	857 	-15 	-15
Cardiovascular
Zetia 	92 	145 	137 	103 	98 	482 	-37 	-41
Vytorin 	41 	53 	39 	47 	43 	182 	-23 	-27
Atozet 	112 	122 	115 	111 	105 	453 	-9 	-16
Alliance Revenue - Adempas (4) 74 	53 	79 	83 	65 	281 	38 	38
Adempas (5) 55 	56 	57 	55 	53 	220 	-2 	-10
Diabetes (6)
Januvia 	809 	774 	854 	821 	857 	3,306 	5 	2
Janumet 	486 	503 	490 	506 	472 	1,971 	-3 	-6
Women's Health
Implanon / Nexplanon 	183 	195 	132 	189 	165 	680 	-6 	-7
NuvaRing 	45 	63 	63 	58 	53 	236 	-28 	-30
Diversified Brands
Singulair 	107 	155 	100 	82 	124 	462 	-31 	-35
Cozaar / Hyzaar 	90 	102 	98 	91 	94 	386 	-12 	-16
Arcoxia 	56 	70 	65 	68 	54 	258 	-20 	-22
Follistim AQ 	52 	41 	44 	50 	57 	193 	25 	21
Nasonex 	43 	71 	49 	41 	57 	218 	-39 	-40
Other Pharmaceutical (7) 1,197 	1,338 	1,207 	1,292 	1,340 	5,173 	-11 	-13
ANIMAL HEALTH 	1,418 	1,214 	1,101 	1,220 	1,168 	4,703 	17 	15
Livestock 	819 	739 	648 	758 	794 	2,939 	11 	9
Companion Animals 	599 	475 	453 	462 	374 	1,764 	26 	24
Other Revenues (8) (13) 	188 	92 	11 	(21) 	270 	-107 	-21
(6) Total Diabetes sales were $1,363 million in the first quarter of 2021 and $1,353 million, $1,418 million, $1,405 million and $1,412 million in
the first, second, third and fourth quarters of 2020, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue
hedging activities.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $1,809 million in the first quarter of 2021 and $2,155 million, $1,418 million, $2,521 million and $2,163 million in
the first, second, third and fourth quarters of 2020, respectively.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of
sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
2020 	1Q
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
5

-- 6 of 9 --

1Q 2021 	1Q 2020 	% Change 	1Q 2021 	1Q 2020 	% Change 	1Q 2021 	1Q 2020 	% Change
TOTAL SALES (1) $12,080 	$12,057 	- 	$5,136 	$5,137 	- 	$6,943 	$6,920 	-
PHARMACEUTICAL 	10,675 	10,655 	- 	4,641 	4,714 	-2 	6,034 	5,941 	2
Oncology
Keytruda 	3,899 	3,284 	19 	2,181 	1,906 	14 	1,718 	1,378 	25
Alliance Revenue - Lynparza (2) 228 	145 	57 	118 	85 	39 	110 	60 	81
Alliance Revenue - Lenvima (2) 130 	128 	1 	85 	90 	-5 	44 	38 	17
Vaccines (3)
Gardasil / Gardasil 9 	917 	1,097 	-16 	313 	461 	-32 	604 	636 	-5
ProQuad / M-M-R II / Varivax 	449 	435 	3 	333 	333 	- 	117 	102 	14
Pneumovax 23 	171 	256 	-33 	73 	182 	-60 	99 	75 	32
RotaTeq 	158 	222 	-29 	118 	140 	-16 	41 	82 	-50
Vaqta 	34 	60 	-43 	25 	30 	-17 	9 	30 	-70
Hospital Acute Care
Bridion 	340 	299 	14 	167 	143 	17 	173 	157 	10
Prevymis 	82 	60 	37 	35 	26 	33 	47 	33 	41
Noxafil 	67 	94 	-29 	15 	8 	96 	52 	87 	-40
Primaxin 	65 	51 	26 	-97 	65 	51 	27
Cancidas 	57 	55 	4 	3 	3 	-4 	55 	52 	5
Invanz 	57 	64 	-12 	4 	6 	-26 	52 	59 	-11
Zerbaxa 	(8) 	37 	-121 	(2) 	20 	-110 	(6) 	16 	-135
Immunology
Simponi 	214 	215 	- 	214 	215 	-
Remicade 	85 	88 	-3 	85 	88 	-3
Neuroscience
Belsomra 	79 	79 	- 	18 	27 	-33 	61 	53 	17
Virology
Isentress / Isentress HD 	209 	245 	-15 	71 	75 	-6 	138 	170 	-19
Cardiovascular
Zetia 	92 	145 	-37 	2 	(2) 	-199 	90 	147 	-39
Vytorin 	41 	53 	-23 	2 	3 	-29 	38 	50 	-23
Atozet 	112 	122 	-9 	112 	122 	-9
Alliance Revenue - Adempas (4) 74 	53 	38 	68 	49 	40 	6 	5 	22
Adempas (5) 55 	56 	-2 	55 	56 	-2
Diabetes (6)
Januvia 	809 	774 	5 	348 	355 	-2 	461 	419 	10
Janumet 	486 	503 	-3 	84 	113 	-26 	401 	390 	3
Women's Health
Implanon / Nexplanon 	183 	195 	-6 	141 	149 	-6 	42 	45 	-6
NuvaRing 	45 	63 	-28 	21 	26 	-20 	24 	37 	-34
Diversified Brands
Singulair 	107 	155 	-31 	4 	5 	-8 	102 	151 	-32
Cozaar / Hyzaar 	90 	102 	-12 	3 	7 	-56 	87 	95 	-8
Arcoxia 	56 	70 	-20 	56 	70 	-20
Follistim AQ 	52 	41 	25 	25 	21 	23 	27 	21 	28
Nasonex 	43 	71 	-39 	2 	6 	-65 	41 	65 	-37
Other Pharmaceutical (7) 1,197 	1,338 	-11 	384 	447 	-14 	814 	886 	-8
ANIMAL HEALTH 	1,418 	1,214 	17 	437 	384 	14 	981 	830 	18
Livestock 	819 	739 	11 	157 	162 	-3 	662 	577 	15
Companion Animals 	599 	475 	26 	280 	222 	26 	319 	253 	26
Other Revenues (8) (13) 	188 	-107 	58 	39 	51 	(72) 	149 	-149
Sum of U.S. plus international may not equal global due to rounding.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $1,363 million and $1,353 million on a global basis in the first quarter of 2021 and 2020, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
(3) Total Vaccines sales were $1,809 million and $2,155 million on a global basis in the first quarter of 2021 and 2020, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FIRST QUARTER 2021
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
6

-- 7 of 9 --

2021 	% Change
TOTAL PHARMACEUTICAL 	$10,675 	$10,655 	$9,679 	$11,320 	$11,367 	$43,021 	-
United States 	4,641 	4,714 	4,270 	5,218 	5,247 	19,449 	-2
% Pharmaceutical Sales 	43.5% 	44.2% 	44.1% 	46.1% 	46.2% 	45.2%
Europe (1) 2,663 	2,543 	2,196 	2,549 	2,709 	9,997 	5
% Pharmaceutical Sales 	24.9% 	23.9% 	22.7% 	22.5% 	23.8% 	23.2%
China 	894 	846 	811 	990 	888 	3,534 	6
% Pharmaceutical Sales 	8.4% 	7.9% 	8.4% 	8.7% 	7.8% 	8.2%
Japan 	708 	789 	847 	805 	847 	3,288 	-10
% Pharmaceutical Sales 	6.6% 	7.4% 	8.8% 	7.1% 	7.5% 	7.6%
Asia Pacific (other than China and Japan) 	614 	613 	555 	601 	603 	2,372 	-
% Pharmaceutical Sales 	5.8% 	5.8% 	5.7% 	5.3% 	5.3% 	5.5%
Eastern Europe/Middle East/Africa 	463 	490 	416 	419 	365 	1,689 	-5
% Pharmaceutical Sales 	4.3% 	4.6% 	4.3% 	3.7% 	3.2% 	3.9%
Latin America 	422 	419 	399 	477 	474 	1,768 	1
% Pharmaceutical Sales 	4.0% 	3.9% 	4.1% 	4.2% 	4.2% 	4.1%
Canada 	203 	212 	160 	216 	194 	782 	-4
% Pharmaceutical Sales 	1.9% 	2.0% 	1.7% 	1.9% 	1.7% 	1.8%
Other 	67 	29 	25 	45 	40 	142 	131
% Pharmaceutical Sales 	0.6% 	0.3% 	0.3% 	0.4% 	0.4% 	0.3%
1Q
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe primarily represents all European Union countries, the European Union accession markets and the United Kingdom.
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2020
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
7

-- 8 of 9 --

OTHER (INCOME) EXPENSE, NET
1Q21 	1Q20
Interest income 	(11)	$ 	(25)	$
Interest expense 	200 	212
Exchange losses 	47 	54
Income from investments in equity securities, net (1) (574) 	(52)
Net periodic defined benefit plan (credit) cost other than service cost 	(89) 	(90)
Other, net 	(21) 	(28)
Total 	(448)	$ 	71	$
(1) Includes realized and unrealized gains and losses from investments in equity securities either owned directly or through
ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are
determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one
quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
8

-- 9 of 9 --